Apotex Receives First Canadian Health Canada Approval for Generic Ozempic (Semaglutide) Alternative

Key Takeaways

• Apotex is the first Canadian-based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic (semaglutide)
• The approved product, Apo-Semaglutide Injection, could provide more affordable diabetes treatment options for Canadian patients
• This milestone reinforces Apotex’s position as Canada’s largest Canadian-based global health company and leader in generic medications

---

TORONTO, May 1, 2026 — Apotex Inc., Canada’s largest Canadian-based global health company, announced that Health Canada has approved Apo-Semaglutide Injection, marking a significant milestone as the first Canadian pharmaceutical company to receive authorization for a generic equivalent of Ozempic (semaglutide injection).

Market Impact and Patient Access

This approval represents a major development in the Canadian diabetes treatment landscape, potentially improving access to semaglutide therapy through more affordable generic alternatives. Ozempic, originally developed by Novo Nordisk, has become a cornerstone treatment for type 2 diabetes and has gained significant attention for its weight management benefits.

The introduction of a generic semaglutide option could substantially reduce treatment costs for patients and healthcare systems across Canada. Generic medications typically cost 20-90% less than their brand-name counterparts, making essential treatments more accessible to a broader patient population.

Apotex’s Strategic Achievement

This regulatory success strengthens Apotex’s position in the competitive pharmaceutical market and demonstrates the company’s capability to develop complex generic formulations. The approval process for biosimilar and generic versions of advanced diabetes medications requires extensive clinical data and regulatory expertise.

“This approval reinforces Apotex’s leadership in bringing high-quality, affordable alternatives to Canadians,” the company stated, highlighting their commitment to improving healthcare accessibility.

Regulatory and Clinical Significance

Health Canada’s approval indicates that Apo-Semaglutide Injection has met stringent safety, efficacy, and quality standards equivalent to the original Ozempic formulation. The regulatory review process typically involves comprehensive analysis of manufacturing processes, clinical trial data, and bioequivalence studies.

The timing of this approval is particularly significant given the growing demand for GLP-1 receptor agonists like semaglutide, both for diabetes management and weight loss applications. Supply constraints and high costs have limited patient access to these treatments, making generic alternatives increasingly important for healthcare sustainability.

---

Frequently Asked Questions

What does this approval mean for Canadian diabetes patients?

Canadian patients with type 2 diabetes will have access to a more affordable generic version of semaglutide (Ozempic), potentially reducing treatment costs significantly while maintaining the same therapeutic benefits.

When will Apo-Semaglutide Injection be available in pharmacies?

While Health Canada has approved the medication, Apotex has not yet announced the specific launch timeline. Generic medications typically become available within months of regulatory approval.

How does the generic version compare to brand-name Ozempic?

Apo-Semaglutide Injection must demonstrate bioequivalence to Ozempic, meaning it provides the same therapeutic effects, safety profile, and dosing as the original medication, but at a lower cost.